Royalty Pharma Stock as a Diversified Alternative to Revolution Medicines
Revolution Medicines (RVMD) recently received FDA breakthrough therapy designation for its drug RASONQUE, targeting metastatic pancreatic cancer. This development has driven the stock up by over 300% in the past year. While this is positive news, investors may consider Royalty Pharma (RPRX), which holds a royalty interest in Revolution Medicines' pipeline and offers exposure to multiple pharmaceutical products across various drug developers. Royalty Pharma operates by providing upfront capital to biopharmaceutical companies in exchange for future royalties on drug sales. It currently has investments in 35 approved drugs and 17 under development, including RASONQUE. The company estimates that RASONQUE could generate up to $11 billion in peak sales with potential royalty income of $340 million. In addition to its diversified portfolio, Royalty Pharma offers a dividend yield of approximately 1.6%, making it an attractive option for investors seeking both growth and income.
Tickers: $RVMD
Topics: Breakthrough Therapy Designation Cancer Drugs FDA Royalty Pharma